8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 3, 2011

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction
of incorporation) 1-14041
(Commission
File Number) 04-2882273
(I.R.S. Employer
Identification No.)

400 Wood Road	02184
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02(c) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 6, 2011, Haemonetics Corporation announced that Richard J. Meelia was elected to serve as Non-Executive Chairman of the Board of Directors effective as of June 3, 2011.

Mr. Meelia will receive an annual retainer equal to $250,000 and initial equity grant valued at $300,000 and split equally between restricted stock units and non-qualified stock options. His annual retainer will be pro-rated to reflect the remainder of the fiscal year ending March 31, 2012 in which director cash compensation is paid. Mr. Meelia’s equity grant consists of a grant of 2,275 restricted stock units and 8,484 non-qualified stock options with an exercise price of $65.92. These shares will vest one year from the grant date.

Item 7.01 Regulation FD Disclosure.

The company’s press release announcing the election of Mr. Meelia is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

99.1: Press Release of Haemonetics Corporation dated June 6, 2011 announcing the election of Richard J. Meelia Non-Executive Chairman of the Haemonetics Board of Directors.

2

SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HAEMONETICS CORPORATION (Registrant)
Date: June 7, 2011	/s/ Christopher Lindop
	Christopher Lindop, Chief Financial Officer
	and VP Business Development

EXHIBIT INDEX

99.1 Press Release of Haemonetics Corporation dated June 6, 2011 announcing the election of Richard J. Meelia Non-Executive Chairman of the Haemonetics Board of Directors.

EX-99.1

Exhibit 99.1

News Release

FOR RELEASE:	CONTACT:
Date     June 6, 2011	Bryanne Salmon
Time     8:00 am Eastern	Tel. (781) 356-9613
	Alt. (617) 633-2297
	bsalmon@haemonetics.com

Richard J. Meelia Elected Chairman of Haemonetics Board of Directors

Braintree, MA, June 6, 2011— Haemonetics Corporation (NYSE:HAE) announced today that its Board of Directors elected Rich Meelia to join the Board and assume the role of Chairman, effective immediately. Meelia, 62, will retire as Covidien plc’s President and Chief Executive Officer on July 1, 2011. He will remain as Non-Executive Chairman of Covidien. Prior to serving as Covidien’s Chief Executive Officer, Meelia was President and Chief Executive Officer of Tyco Healthcare and President of Kendall Healthcare Products Company, the foundation of both the Tyco Healthcare business and Covidien.

Mr. Meelia, who has close to 40 years of healthcare industry experience, formerly served on the Haemonetics Board from 2005-2009. He resigned to focus on his CEO responsibilities at Covidien. Early in his career, he was promoted through a series of sales and marketing positions at the Pharmaseal and McGaw divisions of American Hospital Supply, where he ultimately became Vice President of Sales and Marketing. Following his career at American Hospital Supply, and before joining Kendall Healthcare, Mr. Meelia was President of Infusaid, Inc. a $30 million division of Pfizer that marketed implantable infusion pumps and ports.

Brian Concannon, Haemonetics’ President and Chief Executive Officer said, “Rich’s exceptional leadership, proven record of driving transformational change in healthcare, and his past experience at Haemonetics makes him the ideal person to lead our Board during this important time in our history.”

“I look forward to rejoining the Haemonetics Board of Directors and serving the Company’s shareholders,” said Mr. Meelia. “Brian and his team have done a terrific job in growing the business and I believe Haemonetics is well-positioned to succeed going forward.”

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.